Company Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
0.549 USD +10.17% Intraday chart for Daré Bioscience, Inc. +18.60% +77.67%

Business Summary

Dare Bioscience, Inc. is a biopharmaceutical company. The Company is engaged in identifying, developing, and marketing a portfolio of differentiated therapies that prioritize women's health and well-being, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Its first product, XACIATO, is a clindamycin phosphate vaginal gel used for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1 and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-GML, DARE-LBT, and DARE-RH1. Ovaprene is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream 3.6% is a proprietary cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder (FSAD).

Number of employees: 28

Sales per Business

USD in Million2021Weight2022Weight Delta
Women's Health
100.0 %
0 nan % 10 100.0 % -

Sales per region

USD in Million2021Weight2022Weight Delta
United States
100.0 %
0 nan % 10 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 57 14-12-31
Chief Tech/Sci/R&D Officer - 21-12-31
Chief Tech/Sci/R&D Officer - 21-12-31
Chief Tech/Sci/R&D Officer - 15-12-31
Chief Tech/Sci/R&D Officer - 18-06-05
Chief Operating Officer 69 -
Corporate Officer/Principal 53 18-05-07
Comptroller/Controller/Auditor 47 18-09-30

Members of the board

Members of the board TitleAgeSince
Director/Board Member 68 14-12-31
Director/Board Member 59 19-11-19
Chairman 75 13-12-31
Chief Executive Officer 57 14-12-31
Director/Board Member 52 18-04-08
Director/Board Member 69 14-09-30
Director/Board Member 64 18-09-12
Director/Board Member 40 21-04-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 98,562,344 96,899,796 ( 98.31 %) 0 98.31 %

Shareholders

NameEquities%Valuation
Vanguard Global Advisers LLC
3.499 %
3,448,612 3.499 % 2 M $
Geode Capital Management LLC
0.9853 %
971,119 0.9853 % 557 422 $
962,062 0.9761 % 552 224 $
Renaissance Technologies LLC
0.7299 %
719,400 0.7299 % 412 936 $
443,512 0.4500 % 254 576 $
BlackRock Institutional Trust Co. NA
0.3935 %
387,837 0.3935 % 222 618 $
247,710 0.2513 % 142 186 $
246,171 0.2498 % 141 302 $
Northern Trust Investments, Inc.(Investment Management)
0.1860 %
183,302 0.1860 % 105 215 $
T. Rowe Price International Ltd.
0.1277 %
125,900 0.1277 % 72 267 $

Company contact information

Daré Bioscience, Inc.

3655 Nobel Drive Suite 260

92122, San Diego

+

http://www.darebioscience.com
address Daré Bioscience, Inc.(DARE)